Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) CFO James M. Frates sold 10,896 shares of the firm's stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $3.47, for a total transaction of $37,809.12. Following the transaction, the chief financial officer now owns 290,988 shares of the company's stock, valued at approximately $1,009,728.36. This represents a 3.61 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Amylyx Pharmaceuticals Stock Up 13.2 %
NASDAQ:AMLX opened at $3.78 on Thursday. The firm has a market cap of $334.92 million, a PE ratio of -0.99 and a beta of -0.51. The company's 50-day moving average price is $3.55 and its two-hundred day moving average price is $4.05. Amylyx Pharmaceuticals, Inc. has a 12 month low of $1.58 and a 12 month high of $7.27.
Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last released its quarterly earnings results on Tuesday, March 4th. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.06). The company had revenue of ($0.67) million during the quarter. On average, research analysts expect that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reissued a "buy" rating and issued a $12.00 target price on shares of Amylyx Pharmaceuticals in a report on Wednesday, March 5th. Three analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $7.33.
Check Out Our Latest Report on Amylyx Pharmaceuticals
Institutional Trading of Amylyx Pharmaceuticals
Several large investors have recently made changes to their positions in the business. Blue Trust Inc. raised its holdings in shares of Amylyx Pharmaceuticals by 232.1% in the fourth quarter. Blue Trust Inc. now owns 6,987 shares of the company's stock valued at $26,000 after buying an additional 4,883 shares during the last quarter. XTX Topco Ltd increased its position in Amylyx Pharmaceuticals by 12.0% in the 4th quarter. XTX Topco Ltd now owns 53,376 shares of the company's stock valued at $202,000 after acquiring an additional 5,704 shares in the last quarter. Northern Trust Corp raised its stake in shares of Amylyx Pharmaceuticals by 11.8% in the fourth quarter. Northern Trust Corp now owns 106,564 shares of the company's stock worth $403,000 after acquiring an additional 11,214 shares during the last quarter. Fox Run Management L.L.C. acquired a new position in shares of Amylyx Pharmaceuticals during the fourth quarter worth approximately $45,000. Finally, Alpine Global Management LLC bought a new stake in shares of Amylyx Pharmaceuticals during the fourth quarter valued at approximately $45,000. Institutional investors own 95.84% of the company's stock.
Amylyx Pharmaceuticals Company Profile
(
Get Free Report)
Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
